局部晚期直肠癌的放化疗

doi:10.3760/cma.j.issn.1673-422X.2015.07.019

摘要/Abstract

摘要： 外科手术治疗是局部晚期直肠癌最主要的治疗手段，但术后局部复发率一直处于较高水平。直肠癌术前和术后放化疗降低了术后局部复发率，并提高了生存率及生命质量。目前辅助放化疗已成为局部晚期直肠癌的标准治疗。靶向药物、新的化疗药物以及高速发展的放疗技术为局部晚期直肠癌的治疗提供了更多的途径。

关键词: 直肠肿瘤, 放射疗法, 化学疗法, 辅助

Abstract: Surgical resection is the primary treatment for locally advanced rectal cancer, but the local recurrence rate of surgical resection is still at a high level. Preoperative and postoperative chemoradiotherapy not only decreases the local recurrence rate of surgical resection, but also elevates the survival rate and life quality. Recently, adjuvant chemoradiotherapy has been applied as the standard therapy for locally advanced rectal cancer. The application of targeted drugs, new chemotherapy drugs and rapid changing radiotherapy technology provide more approaches to the treatment of locally advanced rectal cancer.

Key words: Rectal neoplasms, Radiotherapy, Chemotherapy, adjuvant

龙成，李国权，姜永梅，易铁男，孙秋实. 局部晚期直肠癌的放化疗[J]. 国际肿瘤学杂志, 2015, 42(7): 545-547.

Long Cheng, Li Guoquan, Jiang Yongmei, Yi Tienan, Sun Qiushi. Chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2015, 42(7): 545-547.

参考文献

［1］ Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRCCR07 and NCICCTGCO16 randomized clinical trial［J］. Lancet, 2009, 373(9666): 821-828. ［2］ Greto D, Paiar F, Saieva C, et al. Neoadjuvant oxaliplatin and 5fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a singleinstitution experience［J］. Radiol Med, 2013, 118(4): 570-582. ［3］ Fitzgerald TL, Biswas T, O′Brien K, et al. Neoadjuvant radiotherapy for rectal cancer: adherence to evidencebased guidelines in clinical practice［J］. World J Surg, 2013, 37(3): 639-645. ［4］ Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials［J］. Lancet, 2001, 358 (9290): 1291-304. ［5］ Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for highrisk rectal carcinoma［J］. N Engl J Med, 1991, 324(11): 709-715. ［6］冯瑞, 李明焕, 于金明. 158例Ⅱ和Ⅲ期直肠癌根治术后不同治疗方法疗效分析［J］. 中华放射肿瘤学杂志, 2009, 18(3): 224-225. ［7］ Tulchinsky H, Shmueli E, Figer A, et al. An interval>7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and diseasefree survival in patients with locally advanced rectal cancer［J］. Ann Surg Oncol, 2008, 15(10): 2661-2667. ［8］ Lim SB, Choih S, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers［J］. Ann Surg, 2008, 248 (2): 243-251. ［9］ Samuelian JM, Callister MD, Ashman JB, et al. Reduced acute bowel toxicity in patients treated with intensitymodulated radiotherapy for rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82 (5): 1981-1987. ［10］ Jabbour SK, Patel S, Herman JM, et al. Intensitymodulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits［J］. Int J Surg Oncol, 2012, 82(5): 1-7. ［11］ Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomized, multicentre, noninferiority, phase 3 trial［J］. Lancet Oncol, 2012, 13(6): 579-588. ［12］ Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR01 randomized phase Ⅲ trial［J］. J Clin Oncol, 2011, 29(20): 2773-2780. ［13］ Gérard JP, Azria D, GourgouBourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase Ⅲ trial ACCORD 12/0405Prodige 2［J］. J Clin Oncol, 2010, 28(10): 1638-1644. ［14］ Gérard JP, Azria D, GourgouBourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer［J］. J Clin Oncol, 2012, 30(36): 4558-4565. ［15］ Rdel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locallyadvanced rectal cancer: initial results of the German CAO/ARO/AIO04 randomised phase 3 trial［J］. Lancet Oncol, 2012, 13(7): 679-687. ［16］ Hong YS, Kim DY, Lim SB, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: longterm results of a Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 79(4): 1171-1178. ［17］ Gollins S, Sun Myint A, Haylock B, et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imagingdefined locally advanced rectal cancer: impact on longterm clinical outcomes［J］. J Clin Oncol, 2011, 29(8): 1042-1049. ［18］ Erben P, Strbel P, Horisberger K, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximabbased chemoradiotherapy in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4): 1032-1038. ［19］ Kim SY, Shim EK, Yeo HY, et al. Kras mutation statusand clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase Ⅱ trials［J］. Int J Radiat Oncol Biol Phys, 2013, 85(1): 201-207. ［20］ Dewdney A, Cunningham D, Taberbero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with highrisk rectal cancer(EXPERTC)［J］. J Clin Oncol, 2012, 30(14): 1620-1627. ［21］ Willett CG, Duda DG, Ancukiewicz M, et al. Asafety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase Ⅰ/Ⅱ study compared with standard chemoradiation in locally advanced rectal cancer［J］. Oncologist, 2010, 15(8): 845-851. ［22］ Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabinebased chemoradiotherapy in magnetic resonance imaging defined poorprognosis locally advanced rectal cancer: the AVACROSS study［J］. Oncologist, 2011, 16(5): 614-620. ［23］ Dipetrillo T, Pricolo V, Lagaresgarcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5fluorouracil, and radiation for rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(1): 124-129.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[3]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[5]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[6]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[7]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[8]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[9]	杨博, 付茂勇. 单孔胸腔镜下左上肺舌段癌袖式切除同期行右肺上叶癌切除术1例[J]. 国际肿瘤学杂志, 2024, 51(2): 126-128.
[10]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[11]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[12]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[13]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[14]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[15]	崔腾璐, 孙鹏飞. 鼻咽低级别乳头状腺癌综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(6): 382-384.